UKPDS: tablets or insulin for new type 2 diabetes

Overview

UKPDS Group. Lancet 1998 · PMID 9742976

Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.

Does the study support the specific claim? Partly · Methodological quality: high

Original publication

Plain-language summary

Scientific in-depth review

1. Full reference

Authors

UKPDS Group

Journal

Lancet

Year

1998

Identifier

PMID 9742976

Verification

verified – PubMed E-utilities efetch, 2026-10-25

Retracted

no

Corrections

PubMed lists: ErratumIn (Lancet 1999 Aug 14;354(9178):602)

Extent checked

abstract only

Conflicts of interest and funding

not stated in abstract

2. Research question

Intensive control with sulfonylurea or insulin vs diet on complications

3. Study design and population

Study design

Randomised controlled trial – Multicentre RCT (UKPDS 33)

Population

Newly diagnosed type 2 diabetes, median age 54

Country

UK

Period

Median about 10 years

Sample size

3,867

Inclusion and exclusion criteria

As described in the abstract; details not available in abstract.

4. Methods and endpoints

Exposure / intervention

Intensive policy with chlorpropamide, glibenclamide, glipizide or insulin (FPG <6 mmol/L)

Comparator

Conventional policy with diet

Endpoints

Any diabetes-related endpoint, diabetes-related death, all-cause mortality

Statistical methods

Intention to treat

5. Actual results

Results

HbA1c 7.0% vs 7.9%. Any diabetes-related endpoint -12% (95% CI 1-21; p=0.029); diabetes-related death -10% (n.s.); all-cause mortality -6% (n.s.). Microvascular -25% (7-40). No difference between agents incl. insulin. Major hypoglycaemia per year: 0.7% conventional, 1.0% chlorpropamide, 1.4% glibenclamide, 1.8% insulin. Weight +2.9 kg intensive; insulin +4.0 kg.

Absolute risks

not reported

Authors' conclusion

Intensive control by sulfonylureas or insulin substantially decreases microvascular complications, but not macrovascular disease.

6. Strengths

• Landmark long-term RCT
• Newly diagnosed population

7. Weaknesses

• Open-label
• Older drug regimens

8. Risk of bias

Orienting tool

RoB 2

Type of assessment

simplified assessment (abstract only)

Full formal assessment

no

Overall risk of bias

low

Rationale

Robust randomisation; objective endpoints.

9. Assessment of the statistical interpretation

Microvascular benefit robust; macro non-significant.

10. Relevance to the specific claim

Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.

11. Independent contrary findings

12. Transferability to Germany and Europe

UK; directly relevant.

13. Overall methodological judgement

High-quality RCT showing benefit of intensive control including insulin.

14. Open questions

None beyond those stated.

15. Linked fact checks

• Insulin is the single and only cause of obesity (local or generalised) because it is the only hormone that builds fat and blocks fat breakdown (lipolysis). – Studies supporting the claim
• Insulin (and injected insulin) is a principal driver of atherosclerosis. – Studies contradicting or limiting the claim
• Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality. – Studies with mixed or unclear results
• Insulin therapy in type 2 diabetes roughly doubles all-cause mortality and raises cancer, renal and cardiovascular events, with a dose-response (each extra IU/kg/day +54% mortality), compared with metformin or sulfonylureas. – Studies contradicting or limiting the claim
• Insulin is not needed for glucose to enter cells (the HbA1c inside red blood cells proves it); insulin therefore does not treat diabetes but 'starves' cells, especially the brain, of sugar. – Studies contradicting or limiting the claim
• Sulfonylureas cause more myocardial infarctions, strokes and deaths than metformin (21% higher in 253,690 veterans). – Studies contradicting or limiting the claim
• High blood sugar is not a disease but the body's protective response that 'rescues' you; there is no such thing as diabetes ('drink sugar'); sugar intake has no upper limit; HbA1c is a lie. – Studies contradicting or limiting the claim

Use by the Tayebat archive

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study

Listed in the archive bibliography for 'insulin-injections' without its own interpretation; used as general support for the claim that insulin intensification harms.

A. What was actually studied?

Intensive control with sulfonylurea or insulin vs diet on complications

B. What did the authors find?

Microvascular -25%; more hypoglycaemia and weight gain with insulin.

C. What conclusions do the authors themselves draw?

Intensive control by sulfonylureas or insulin substantially decreases microvascular complications, but not macrovascular disease.

D. What does the archive derive from it?

Bibliography source on hypoglycaemia and weight gain with insulin.

E. Is this derivation scientifically justified?

Archive omits that insulin-based intensive therapy reduced microvascular complications by 25% and did not increase macrovascular events.

Adequacy of the interpretation (by the archive)

taken out of context